Recently, IL-17A inhibitors were proved to be novel bDMARDs for several autoimmune diseases, including psoriasis [28], rheumatoid arthritis [29, 30], and inflammatory bowel disease [31]. This evidence concerns the gene IL17A and psoriasis.